NBW Capital LLC boosted its holdings in Repligen (NASDAQ:RGEN) by 10.1% during the 1st quarter, Holdings Channel reports. The institutional investor owned 47,818 shares of the biotechnology company’s stock after buying an additional 4,373 shares during the quarter. NBW Capital LLC’s holdings in Repligen were worth $1,730,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of the business. Victory Capital Management Inc. grew its position in Repligen by 38.9% during the 1st quarter. Victory Capital Management Inc. now owns 5,755 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 1,612 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Repligen by 66.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 10,490 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 4,190 shares in the last quarter. First Manhattan Co. grew its position in Repligen by 16.7% during the 4th quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,500 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Repligen during the 4th quarter worth approximately $462,000. Finally, Alps Advisors Inc. purchased a new position in Repligen during the 1st quarter worth approximately $483,000. Hedge funds and other institutional investors own 87.69% of the company’s stock.
Shares of NASDAQ:RGEN opened at $40.90 on Friday. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 55.97, a price-to-earnings-growth ratio of 2.69 and a beta of 0.83. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.08 and a current ratio of 12.22.
Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.02. The company had revenue of $44.80 million during the quarter, compared to analyst estimates of $43.88 million. Repligen had a net margin of 18.48% and a return on equity of 6.06%. The company’s revenue for the quarter was up 46.4% on a year-over-year basis. During the same quarter last year, the business posted $0.15 EPS. equities research analysts expect that Repligen will post 0.7 earnings per share for the current fiscal year.
In other Repligen news, Director Thomas F. Ryan, Jr. sold 4,696 shares of Repligen stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total transaction of $169,807.36. Following the completion of the sale, the director now owns 9,700 shares of the company’s stock, valued at approximately $350,752. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Roy T. Eddleman sold 120,000 shares of Repligen stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $40.62, for a total transaction of $4,874,400.00. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
Several research firms have weighed in on RGEN. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research report on Thursday, April 26th. TheStreet upgraded shares of Repligen from a “c” rating to a “b-” rating in a research report on Tuesday, March 13th. Finally, BidaskClub upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Repligen presently has a consensus rating of “Buy” and an average price target of $44.25.
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.